Income Statement BriaCell Therapeutics Corp.

Stocks

BCT

CA1079303071

Biotechnology & Medical Research

Market Closed - Toronto S.E. 01:29:59 25/08/2026 am IST			5-day change	1st Jan Change
4.820 ^CAD	-13.31%		+2.55%	-50.82%

24/08	BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+	CI
06/08	BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study	MT

8557.o0LWkmm7AlqE6YSIN1IzAvi2sg3TRNOTFEcjEgsQZDI.0iyB6xqLd2_cvvfMYwd4MILyh1ygMby-egF6fDxcE2DUd67dIsljK_GK6w

Published financial data: BRIACELL THERAPEUTICS CORP.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Selling General & Admin Expenses, Total	37.18L	72.67L	85.15L	66.49L	63.91L
Stock-Based Compensation (IS)	19.68L	-	-	-	-
R&D Expenses	12.87L	80.21L	1.48Cr	2.67Cr	2.08Cr
Other Operating Expenses, Total	69.73L	1.53Cr	2.33Cr	3.33Cr	2.72Cr
Operating Income	-69.73L	-1.53Cr	-2.33Cr	-3.33Cr	-2.72Cr
Interest Expense, Total	-46.1T	-979	-	-	-36.98T
Interest And Investment Income	3.15T	1L	9L	3L	1L
Net Interest Expenses	-42.95T	1L	9L	3L	82.98T
Income (Loss) On Equity Invest.	-	-	-	-1L	-2L
Currency Exchange Gains (Loss)	-21.78L	-30.73T	-40.87T	-25.45T	-24.94T
Other Non Operating Income (Expenses)	89.67L	-1.17Cr	21.2L	2.82Cr	8L
EBT, Excl. Unusual Items	-2L	-2.68Cr	-2.03Cr	-49.32L	-2.66Cr
Gain (Loss) On Sale Of Investments	-	-	-	-	56.47T
Other Unusual Items	-2L	-	-	-	-
EBT, Incl. Unusual Items	-4L	-2.68Cr	-2.03Cr	-49.32L	-2.66Cr
Earnings From Continuing Operations	-4L	-2.68Cr	-2.03Cr	-49.32L	-2.66Cr
Net Income to Company	-4L	-2.68Cr	-2.03Cr	-49.32L	-2.66Cr
Minority Interest	-	-	-	1L	2L
Net Income - (IS)	-4L	-2.68Cr	-2.03Cr	-47.91L	-2.63Cr
Net Income to Common Incl Extra Items	-4L	-2.68Cr	-2.03Cr	-47.91L	-2.63Cr
Net Income to Common Excl. Extra Items	-4L	-2.68Cr	-2.03Cr	-47.91L	-2.63Cr
Per Share Items
Net EPS - Basic	-14.22	-259.83	-194.97	-43.68	-62.19
Basic EPS - Continuing Operations	-14.22	-259.83	-194.97	-43.68	-62.19
Basic Weighted Average Shares Outstanding	30.13T	1L	1L	1L	4L
Net EPS - Diluted	-14.22	-259.83	-194.97	-43.68	-62.19
Diluted EPS - Continuing Operations	-14.22	-259.83	-194.97	-43.68	-62.19
Diluted Weighted Average Shares Outstanding	30.13T	1L	1L	1L	4L
Normalized Basic EPS	-4.71	-162.39	-121.86	-26.82	-38.73
Normalized Diluted EPS	-4.71	-162.39	-121.86	-26.82	-38.73
Supplemental Items
EBITDA	-69.58L	-1.53Cr	-2.33Cr	-3.32Cr	-2.71Cr
EBITA	-69.58L	-1.53Cr	-2.33Cr	-3.33Cr	-2.72Cr
EBIT	-69.73L	-1.53Cr	-2.33Cr	-3.33Cr	-2.72Cr
EBITDAR	-69.18L	-	-2.27Cr	-3.27Cr	-2.66Cr
Normalized Net Income	-1L	-1.68Cr	-1.27Cr	-29.42L	-1.64Cr
Interest on Long-Term Debt	40.67T	979	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	36.78L	72.67L	79.36L	61.52L	59.34L
Research And Development Expense From Footnotes	13.15L	80.21L	1.53Cr	2.72Cr	2.13Cr
Net Rental Expense, Total	39.97T	-	6L	5L	5L
Imputed Operating Lease Interest Expense	68.28T	-	-	-	-
Imputed Operating Lease Depreciation	-28.31T	-	-	-	-
Stock-Based Comp., R&D Exp. (Total)	-	4L	10.73L	7L	1L
Stock-Based Comp., G&A Exp. (Total)	-	26.39L	11.21L	10.69L	7L
Stock-Based Comp., Other (Total)	19.68L	-	-	-	-
Total Stock-Based Compensation	19.68L	30.75L	21.94L	18.04L	8L

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	5.73Cr	4.1Cr	2.13Cr	9L	1.05Cr
Short Term Investments	-	-	-	-	73.72L
Total Cash And Short Term Investments	5.73Cr	4.1Cr	2.13Cr	9L	1.79Cr
Other Receivables	12.57T	24.1T	18.87T	7L	-
Total Receivables	12.57T	24.1T	18.87T	7L	-
Prepaid Expenses	5L	12.81L	56.79L	20.55L	20.6L
Total Current Assets	5.78Cr	4.23Cr	2.69Cr	36.54L	1.99Cr
Gross Property Plant And Equipment	-	-	-	5L	5L
Accumulated Depreciation	-	-	-	-68.63T	-2L
Net Property Plant And Equipment	-	-	-	4L	3L
Long-term Investments	2	2	2	4L	5L
Other Intangibles, Total	2L	2L	2L	2L	2L
Other Long-Term Assets, Total	-	-	-	12.12L	7L
Total Assets	5.8Cr	4.26Cr	2.72Cr	58.72L	2.16Cr
Liabilities
Accounts Payable, Total	5L	5L	11.24L	71.71L	32.84L
Accrued Expenses, Total	48.53T	5L	7L	3L	7L
Short-term Borrowings	-	-	-	-	-
Other Current Liabilities	-	-	-	-	-
Total Current Liabilities	6L	9L	18.01L	74.61L	39.78L
Long-Term Debt	25.99T	-	-	-	-
Unearned Revenue Non Current	-	-	-	-	-
Other Non Current Liabilities	2L	3.13Cr	2.91Cr	10.96L	3L
Total Liabilities	8L	3.22Cr	3.09Cr	85.57L	43.16L
Common Stock, Total	5.48Cr	6.56Cr	6.96Cr	7.22Cr	10Cr
Additional Paid In Capital	-	52.28L	-	-	-
Retained Earnings	-1.58Cr	-6.03Cr	-8.07Cr	-8.54Cr	-11Cr
Comprehensive Income and Other	1.82Cr	-1L	72.83L	1.09Cr	2.79Cr
Total Common Equity	5.73Cr	1.03Cr	-37.77L	-23.82L	1.79Cr
Minority Interest	-	-	-	-3L	-5L
Total Equity	5.73Cr	1.03Cr	-37.77L	-26.85L	1.73Cr
Total Liabilities And Equity	5.8Cr	4.26Cr	2.72Cr	58.72L	2.16Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1L	1L	1L	1L	18.84L
ECS Total Common Shares Outstanding	1L	1L	1L	1L	18.84L
Book Value / Share	562.51	99.84	-35.45	-19.54	9.49
Tangible Book Value	5.7Cr	1.01Cr	-39.92L	-25.82L	1.77Cr
Tangible Book Value Per Share	560.09	97.61	-37.47	-21.18	9.39
Total Debt	25.99T	0	0	0	0
Net Debt	-5.72Cr	-4.1Cr	-2.13Cr	-9L	-1.79Cr
Debt Equivalent Oper. Leases	3L	-	46.33L	39.7L	36.59L
Minority Interest, Total (Incl. Fin. Div)	-	-	-	-3L	-5L
Equity Method Investments, Total	-	-	-	4L	5L
Account Code - Inventory Valuation	-	-	3	3	3
Machinery, Total	-	-	-	5L	5L
Full Time Employees	5	-	16	-	-
Part Time Employees	1	-	-	-	-

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Net Income	-4L	-2.68Cr	-2.03Cr	-47.91L	-2.63Cr
Depreciation & Amortization - CF	-	-	-	68.63T	91.36T
Amortization of Goodwill and Intangible Assets - (CF)	15.26T	15.27T	15.27T	15.27T	15.27T
Depreciation & Amortization, Total	15.26T	15.27T	15.27T	83.9T	1L
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-	-
(Income) Loss On Equity Investments - (CF)	-	-	-	1L	2L
Stock-Based Compensation (CF)	19.68L	30.75L	21.94L	18.04L	8L
Other Operating Activities, Total	-70.21L	1.17Cr	-21.2L	-2.84Cr	-10.59L
Change In Accounts Receivable	9.94T	-11.53T	5.23T	-7L	7L
Change In Accounts Payable	-21.91L	2L	7L	60.47L	-38.87L
Change in Other Net Operating Assets	-1L	-6L	-41.98L	17.39L	12.46L
Cash from Operations	-77.48L	-1.25Cr	-2.37Cr	-2.41Cr	-2.82Cr
Capital Expenditure	-	-	-	-5L	-
Investment in Marketable and Equity Securities, Total	-	-	-	-2L	-76.46L
Cash from Investing	-	-	-	-7L	-76.46L
Short Term Debt Issued, Total	2L	-	-	-	-
Total Debt Issued	2L	-	-	-	-
Short Term Debt Repaid, Total	-5L	-	-	-	-
Total Debt Repaid	-5L	-	-	-	-
Issuance of Common Stock	5.42Cr	65.1L	40.02L	44.19L	4.54Cr
Repurchase of Common Stock	-	-1.02Cr	-47.29T	-	-
Other Financing Activities, Total	1.11Cr	-80.69T	-	-	-
Cash from Financing	6.5Cr	-37.43L	39.54L	44.19L	4.54Cr
Foreign Exchange Rate Adjustments	-	-	-	-	-
Net Change in Cash	5.72Cr	-1.62Cr	-1.98Cr	-2.04Cr	96.32L
Supplemental Items
Levered Free Cash Flow	-58.5L	-68.58L	-1.59Cr	-1.08Cr	-1.89Cr
Unlevered Free Cash Flow	-58.21L	-68.57L	-1.59Cr	-1.08Cr	-1.89Cr
Change In Net Working Capital	34.46L	4L	35.32L	-85.65L	27.52L
Net Debt Issued / Repaid	-3L	-	-	-	-

Fiscal Period: July	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-14.88	-18.99	-41.71	-126.11	-123.56
Return on Total Capital	-16.11	-50.26	-444.01	644.72	-232.14
Return On Equity %	-1.6	-141.25	-619.75	152.63	-362.56
Return on Common Equity	-1.6	-141.25	-619.75	155.58	-339.54
Short Term Liquidity
Current Ratio	103.81	45	14.96	0.49	5.01
Quick Ratio	102.88	43.64	11.81	0.21	4.49
Operating Cash Flow to Current Liabilities	-13.91	-13.27	-13.18	-3.23	-7.08
Long Term Solvency
Total Debt/Equity	0.05	-	-	-	-
Total Debt / Total Capital	0.05	-	-	-	-
LT Debt/Equity	0.05	-	-	-	-
Long-Term Debt / Total Capital	0.05	-	-	-	-
Total Liabilities / Total Assets	1.35	75.74	113.91	145.72	19.93
EBIT / Interest Expense	-151.29	-15.62T	-	-	-735.68
EBITDA / Interest Expense	-150.95	-15.6T	-	-	-732.8
(EBITDA - Capex) / Interest Expense	-150.95	-15.6T	-	-	-732.8
Total Debt / EBITDA	-0	-	-	-	-
Net Debt / EBITDA	8.23	2.69	0.91	0.03	0.66
Total Debt / (EBITDA - Capex)	-0	-	-	-	-
Net Debt / (EBITDA - Capex)	8.23	2.69	0.91	0.03	0.66
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	77.32	119.42	52.27	42.95	-18.49
EBITA, 1 Yr. Growth %	77.32	119.42	52.27	43.25	-18.39
EBIT, 1 Yr. Growth %	77.02	119.16	52.22	43.22	-18.38
Earnings From Cont. Operations, 1 Yr. Growth %	-89.36	94.26	-24.35	-75.71	438.5
Net Income, 1 Yr. Growth %	-89.36	94.26	-24.35	-76.4	449.14
Normalized Net Income, 1 Yr. Growth %	-94.26	96.27	-24.35	-76.81	457.03
Diluted EPS Before Extra, 1 Yr. Growth %	-	-43.34	-24.96	-77.6	42.37
Net Property, Plant and Equip., 1 Yr. Growth %	-	-	-	-	-23.53
Total Assets, 1 Yr. Growth %	11.01T	-26.65	-36.2	-78.38	268.68
Tangible Book Value, 1 Yr. Growth %	-1.58T	-63.18	-139.53	-35.32	-785.32
Common Equity, 1 Yr. Growth %	-1.69T	-62.67	-136.57	-36.93	-850.54
Cash From Operations, 1 Yr. Growth %	512.03	61.08	90.2	1.61	16.76
Levered Free Cash Flow, 1 Yr. Growth %	-2.87T	17.57	131.39	-31.72	74.39
Unlevered Free Cash Flow, 1 Yr. Growth %	-2.64T	18.56	131.41	-31.72	74.17
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	17.39	97.29	82.79	47.54	7.94
EBITA, 2 Yr. CAGR %	17.39	97.29	82.79	47.69	8.12
EBIT, 2 Yr. CAGR %	17.34	97	82.65	47.65	8.12
Earnings From Cont. Operations, 2 Yr. CAGR %	-69.85	158.24	21.22	-57.13	14.37
Net Income, 2 Yr. CAGR %	-69.85	158.24	21.22	-57.75	13.84
Normalized Net Income, 2 Yr. CAGR %	-78.8	160.33	21.85	-58.12	13.65
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-34.79	-59	-43.52
Total Assets, 2 Yr. CAGR %	1.04T	802.85	-31.59	-62.86	-10.72
Tangible Book Value, 2 Yr. CAGR %	668.75	61.78	-61.85	-49.43	110.54
Common Equity, 2 Yr. CAGR %	811.86	69.45	-63.05	-51.97	117.58
Cash From Operations, 2 Yr. CAGR %	36.68	214.04	75.04	39.01	8.92
Levered Free Cash Flow, 2 Yr. CAGR %	55.87	470.27	64.94	25.7	9.12
Unlevered Free Cash Flow, 2 Yr. CAGR %	56.01	446.85	65.64	25.7	9.05
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	20.5	44.62	80.97	68.41	21.06
EBITA, 3 Yr. CAGR %	20.5	44.62	80.97	68.52	21.2
EBIT, 3 Yr. CAGR %	20.45	44.52	80.77	68.43	21.18
Earnings From Cont. Operations, 3 Yr. CAGR %	-53.79	78.58	71.51	-29.06	-0.35
Net Income, 3 Yr. CAGR %	-53.79	78.58	71.51	-29.74	-0.66
Normalized Net Income, 3 Yr. CAGR %	-61.6	74.45	72.43	-29.92	-0.77
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	-54.33	-37.91
Total Assets, 3 Yr. CAGR %	189.7	357.49	273.26	-53.4	-20.18
Tangible Book Value, 3 Yr. CAGR %	333.41	118.75	1.14	-54.51	20.56
Common Equity, 3 Yr. CAGR %	287.08	146.61	1.64	-55.84	20.07
Cash From Operations, 3 Yr. CAGR %	24.9	44.39	165.7	46.01	31.16
Levered Free Cash Flow, 3 Yr. CAGR %	26.63	41.75	322.19	22.93	40.19
Unlevered Free Cash Flow, 3 Yr. CAGR %	26.57	42.06	310.56	23.27	40.14
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	31.87	43.49	43.89	45.78	47.18
EBITA, 5 Yr. CAGR %	31.86	43.49	43.89	45.84	47.28
EBIT, 5 Yr. CAGR %	31.91	43.52	43.81	45.76	47.18
Earnings From Cont. Operations, 5 Yr. CAGR %	-24.76	60.59	37.61	0.91	45.84
Net Income, 5 Yr. CAGR %	-24.76	60.59	37.61	0.33	45.58
Normalized Net Income, 5 Yr. CAGR %	-33.55	60.59	39.78	-1.42	45.95
Total Assets, 5 Yr. CAGR %	131.37	92.97	64.38	67.55	110.62
Tangible Book Value, 5 Yr. CAGR %	133.33	69.14	43.16	21.76	35.61
Common Equity, 5 Yr. CAGR %	133.53	69.9	32.18	28.17	37.81
Cash From Operations, 5 Yr. CAGR %	43.89	52.92	44.5	42.22	85.99
Levered Free Cash Flow, 5 Yr. CAGR %	56.86	65.67	42.18	35.1	145.73
Unlevered Free Cash Flow, 5 Yr. CAGR %	56.7	65.67	42.28	35.27	141.59